From 2e1abe725dbf9808f369a502a0eff47b9b710510 Mon Sep 17 00:00:00 2001 From: =?UTF-8?q?=E7=BB=87=E4=B8=8D=E5=94=A7?= <168611353+XuezhiAsagiri@users.noreply.github.com> Date: Thu, 4 Sep 2025 19:30:59 +0800 Subject: [PATCH 01/10] SERMs MIME-Version: 1.0 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: 8bit Signed-off-by: 织不唧 <168611353+XuezhiAsagiri@users.noreply.github.com> --- content/zh-cn/docs/medicine/SERMs/_index.md | 10 +++++----- 1 file changed, 5 insertions(+), 5 deletions(-) diff --git a/content/zh-cn/docs/medicine/SERMs/_index.md b/content/zh-cn/docs/medicine/SERMs/_index.md index 1cd84f1377..36b4eaa922 100644 --- a/content/zh-cn/docs/medicine/SERMs/_index.md +++ b/content/zh-cn/docs/medicine/SERMs/_index.md @@ -23,12 +23,12 @@ weight: 120 雌二醇,\+,\+,\+,\+,\+,\+,\+,\+,\+,\+ “理想 SERM”,\-,\+,\+,O,O,O,\-,\+,\+,O 巴多昔芬,\-,\+,\+,\+,\+,?,\-,O,\-,? -氯米芬,\-,\+,\+,?,\+,\+,\-,?,\-,O +氯米芬,\-,\+,\+,?,\+,?,\-,?,\-,O 拉索昔芬,\-,\+,\+,\+,?,?,O,O,\-,? -奥培米芬,\-,\+,\+,\+,\+,\+,O,O,\-,O -雷洛昔芬,\-,\+,\+,\+,\+,\+,O,\-,\-,O -他莫昔芬,\-,\+,\+,\+,\+,\+,\+,\-,\-,O -托瑞米芬,\-,\+,\+,\+,\+,\+,\+,\-,\-,O +奥培米芬,\-,\+,\+,\+,\+,?,O,O,\-,O +雷洛昔芬,\-,\+,\+,\+,\+,\-,O,\-,\-,O +他莫昔芬,\-,\+,\+,\+,\+,?,\+,\-,\-,O +托瑞米芬,\-,\+,\+,\+,\+,?,\+,\-,\-,O ``` 注：SHBG - sex hormone binding globulin / 性激素结合球蛋白，一种主要与性激素，尤其是雄激素结合的血浆蛋白；IGF-1 - insulin-like growth factor 1 / 类胰岛素生长因子 1，一种受 GH（生长激素）调控的，主要通过肝脏内分泌与各组织旁分泌 / 自分泌的肽类激素；是发挥 GH 作用的主要激素 From ee5cf92bacc89aa0f1badad2f0d5cfd5fcc956d3 Mon Sep 17 00:00:00 2001 From: =?UTF-8?q?=E7=BB=87=E4=B8=8D=E5=94=A7?= <168611353+XuezhiAsagiri@users.noreply.github.com> Date: Thu, 4 Sep 2025 19:45:53 +0800 Subject: [PATCH 02/10] =?UTF-8?q?=E8=A1=A5=E5=85=85=E6=B3=A8=E6=84=8F?= =?UTF-8?q?=E4=BA=8B=E9=A1=B9=EF=BC=88=E6=AF=94=E5=8D=A1=E9=B2=81=E8=83=BA?= =?UTF-8?q?=EF=BC=89?= MIME-Version: 1.0 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: 8bit Signed-off-by: 织不唧 <168611353+XuezhiAsagiri@users.noreply.github.com> --- content/zh-cn/docs/medicine/antiandrogen/bicalutamide/index.md | 3 ++- 1 file changed, 2 insertions(+), 1 deletion(-) diff --git a/content/zh-cn/docs/medicine/antiandrogen/bicalutamide/index.md b/content/zh-cn/docs/medicine/antiandrogen/bicalutamide/index.md index 3f9a06a17c..9f9cf94a90 100644 --- a/content/zh-cn/docs/medicine/antiandrogen/bicalutamide/index.md +++ b/content/zh-cn/docs/medicine/antiandrogen/bicalutamide/index.md @@ -49,6 +49,7 @@ description: 比卡鲁胺（Bicalutamide）是雄激素受体拮抗剂，一种 - 在开始使用前应当检测血清转氨酶水平，并在服药开始 6 个月内定期监测[^5]。 - 有遗传性半乳糖不耐受、Lapp 乳糖酶缺乏症或葡萄糖-半乳糖吸收障碍的患者不得服用。 - 不可与特非那定、阿司咪唑或西沙比利联合使用。 +- 与已知会延长 QT 间期或能诱导尖端扭转型室性心动过速的药物的合并用药进行仔细评价，如IA类（如奎尼丁、丙吡胺）或III 类（如胺碘酮、索他洛尔、多非利特、伊布利特）抗心律失常药、美沙酮、莫西沙星、抗精神病药等。 ## 使用方式与用量 @@ -77,4 +78,4 @@ description: 比卡鲁胺（Bicalutamide）是雄激素受体拮抗剂，一种 [^3]: Aly. Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy [EB/OL]. *Transfeminine Science*, 2020. 译文：《[比卡鲁胺在女性化激素治疗方面的使用状况，以及医学界对其的接受情况](https://tfsci.mtf.wiki/articles/bica-adoption/)》 [^4]: [维基百科：比卡鲁胺的副作用（英文）](https://en.wikipedia.org/wiki/Side_effects_of_bicalutamide) [^5]: Aly. An Introduction to Hormone Therapy for Transfeminine People [EB/OL]. *Transfeminine Science*, 2018. 译文：《[女性倾向跨性别者的激素治疗简介](https://tfsci.mtf.wiki/articles/transfem-intro/)》 -[^6]: Coleman E, Radix A E, Bouman W P, et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8 [J]. *International Journal of Transgender Health*, 2022, *23*(Suppl 1): S1–S259. DOI: [10.1080/26895269.2022.2100644](https://doi.org/10.1080/26895269.2022.2100644) ——[中文译本](https://project-trans.org/SOC-8) \ No newline at end of file +[^6]: Coleman E, Radix A E, Bouman W P, et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8 [J]. *International Journal of Transgender Health*, 2022, *23*(Suppl 1): S1–S259. DOI: [10.1080/26895269.2022.2100644](https://doi.org/10.1080/26895269.2022.2100644) ——[中文译本](https://project-trans.org/SOC-8) From 2aedee94ba37edb66893cd58d0e3f9b555aed3d5 Mon Sep 17 00:00:00 2001 From: =?UTF-8?q?=E7=BB=87=E4=B8=8D=E5=94=A7?= <168611353+XuezhiAsagiri@users.noreply.github.com> Date: Thu, 4 Sep 2025 19:52:54 +0800 Subject: [PATCH 03/10] =?UTF-8?q?=E4=BC=98=E5=8C=96=E8=A1=A8=E8=BF=B0?= =?UTF-8?q?=EF=BC=88=E8=9E=BA=E5=86=85=E9=85=AF=EF=BC=89?= MIME-Version: 1.0 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: 8bit Signed-off-by: 织不唧 <168611353+XuezhiAsagiri@users.noreply.github.com> --- .../zh-cn/docs/medicine/antiandrogen/spironolactone/index.md | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/content/zh-cn/docs/medicine/antiandrogen/spironolactone/index.md b/content/zh-cn/docs/medicine/antiandrogen/spironolactone/index.md index 9e03b4baba..2ad2dfad1c 100644 --- a/content/zh-cn/docs/medicine/antiandrogen/spironolactone/index.md +++ b/content/zh-cn/docs/medicine/antiandrogen/spironolactone/index.md @@ -7,7 +7,7 @@ description: 螺内酯（Spironolactone）是雄激素受体拮抗剂，一种 请仔细阅读说明书并在医师指导下使用药物。 {{< /notice >}} -螺内酯是保钾利尿药和醛固酮的特异性拮抗剂，用于治疗心衰、低钾血症和高血压等 [^3]。但是，它也会阻断雄激素受体，从而具有抗雄激素特性；不过螺内酯本身不会使睾酮降低，其阻断效力较弱，需服用较大剂量方可充分起效[^1] [^4]。\ +螺内酯是保钾利尿药和醛固酮受体特异性拮抗剂，用于治疗心衰、低钾血症和高血压等 [^3]。但是，它也会拮抗雄激素受体，从而具有抗雄激素特性；不过螺内酯本身不会使睾酮降低，其阻断效力较弱，需服用较大剂量方可充分起效[^1] [^4]。\ 一般对 MtF 而言，和非注射途径的中等剂量雌二醇并用时，睾酮会有大幅下降，但仍高于女性正常范围；顺性别女性用于治疗雄激素相关症状时通常需要 50～200 mg/天，而 MtF 可能需要更高剂量（如 100～300 mg/天，乃至 400 mg/天）方可阻断剩余的雄激素[^1] [^5]，但随之而来的尿频、高血钾等副作用可能会更严重。 ## 基本信息 From 8b773ff7e4b208cc56f27e5b9ab616cbf6e21aab Mon Sep 17 00:00:00 2001 From: =?UTF-8?q?=E7=BB=87=E4=B8=8D=E5=94=A7?= <168611353+XuezhiAsagiri@users.noreply.github.com> Date: Thu, 4 Sep 2025 20:14:33 +0800 Subject: [PATCH 04/10] =?UTF-8?q?=E6=9B=B4=E6=AD=A3=E9=9B=8C=E4=BA=8C?= =?UTF-8?q?=E9=86=87=E4=BB=A3=E8=B0=A2=E9=80=94=E5=BE=84?= MIME-Version: 1.0 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: 8bit 事实上，雌二醇代谢相当依赖CYP1A2。 https://pubmed.ncbi.nlm.nih.gov/11741520/ Signed-off-by: 织不唧 <168611353+XuezhiAsagiri@users.noreply.github.com> --- content/zh-cn/docs/medicine/risk.md | 6 +++--- 1 file changed, 3 insertions(+), 3 deletions(-) diff --git a/content/zh-cn/docs/medicine/risk.md b/content/zh-cn/docs/medicine/risk.md index 78258304d5..c62d509f8e 100644 --- a/content/zh-cn/docs/medicine/risk.md +++ b/content/zh-cn/docs/medicine/risk.md @@ -141,7 +141,7 @@ weight: 10 | 类型 | 性质 | |-|-| -| 雌二醇、雌二醇酯 | 依赖 CYP3A4 代谢[^1] [^2] | +| 雌二醇、雌二醇酯 | 依赖 CYP1A2、CYP3A4 代谢[^1] [^2] | | 醋酸环丙孕酮 | 依赖 CYP3A4 代谢[^6] [^7] | | 醋酸甲羟孕酮 | 依赖 CYP3A4 代谢[^20] | | 螺内酯 | 有诱导 CYP3A4 的作用[^21] [^14]
另可能抑制其它 CYP3A 酶系和 CYP2C11[^31] | @@ -182,7 +182,7 @@ weight: 10 诱导剂,抑制剂 **阿塞那平？**,**氟西汀** **卡马西平**,氟伏沙明 -**莫达芬尼**,**帕罗西汀** +**莫达非尼**,**帕罗西汀** **苯巴比妥**
巴比妥类药或类同,奋乃静 **苯妥英**,瑞波西汀\* **圣约翰草（贯叶连翘）**, @@ -226,4 +226,4 @@ Newsletter*, 2012, 22(4): 3-4. [^31]: Chung W G, Buhler D R. The Effect of Spironolactone Treatment on the Cytochrome P450-Mediated Metabolism of the Pyrrolizidine Alkaloid Senecionine by Hepatic Microsomes from Rats and Guinea Pigs [J]. *Toxicology and Applied Pharmacology*, 1994, 127(2): 314–319. \[DOI: [10.1006/taap.1994.1167](https://doi.org/10.1006/taap.1994.1167)] [^32]: Monroe S E, Levine L, Chang R J, et al. Prolactin-Secreting Pituitary Adenomas. V, Increased Gonadotroph Responsivity in Hyperprolactinemic Women with Pituitary Adenomas [J]. *The Journal of Clinical Endocrinology & Metabolism*, 1981, 52(6): 1171–1178. \[DOI: [10.1210/jcem-52-6-1171](https://doi.org/10.1210/jcem-52-6-1171)] [^33]: ANI Pharmaceuticals Inc. LITHOBID® U.S. Physicians Prescribing Information [EB/OL]. *Drugs@FDA*, 2022. -[^34]: Taylor D M, Barnes T R E, Young A H. The Maudsley® Prescribing Guidelines in Psychiatry [M]. 14th ed. Hoboken, US: John Wiley & Sons, 2021: 851-855. \ No newline at end of file +[^34]: Taylor D M, Barnes T R E, Young A H. The Maudsley® Prescribing Guidelines in Psychiatry [M]. 14th ed. Hoboken, US: John Wiley & Sons, 2021: 851-855. From d82d6b559981a25f0052f4a99aef0114f249cf65 Mon Sep 17 00:00:00 2001 From: =?UTF-8?q?=E7=BB=87=E4=B8=8D=E5=94=A7?= <168611353+XuezhiAsagiri@users.noreply.github.com> Date: Sat, 6 Sep 2025 10:31:23 +0800 Subject: [PATCH 05/10] =?UTF-8?q?=E6=9B=B4=E6=96=B0=20index.md?= MIME-Version: 1.0 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: 8bit 回退 --- content/zh-cn/docs/medicine/antiandrogen/bicalutamide/index.md | 1 - 1 file changed, 1 deletion(-) diff --git a/content/zh-cn/docs/medicine/antiandrogen/bicalutamide/index.md b/content/zh-cn/docs/medicine/antiandrogen/bicalutamide/index.md index 9f9cf94a90..ca6a9f0b0e 100644 --- a/content/zh-cn/docs/medicine/antiandrogen/bicalutamide/index.md +++ b/content/zh-cn/docs/medicine/antiandrogen/bicalutamide/index.md @@ -49,7 +49,6 @@ description: 比卡鲁胺（Bicalutamide）是雄激素受体拮抗剂，一种 - 在开始使用前应当检测血清转氨酶水平，并在服药开始 6 个月内定期监测[^5]。 - 有遗传性半乳糖不耐受、Lapp 乳糖酶缺乏症或葡萄糖-半乳糖吸收障碍的患者不得服用。 - 不可与特非那定、阿司咪唑或西沙比利联合使用。 -- 与已知会延长 QT 间期或能诱导尖端扭转型室性心动过速的药物的合并用药进行仔细评价，如IA类（如奎尼丁、丙吡胺）或III 类（如胺碘酮、索他洛尔、多非利特、伊布利特）抗心律失常药、美沙酮、莫西沙星、抗精神病药等。 ## 使用方式与用量 From b26932c085d29d86ce2d4053efdf5f8c5a922a1c Mon Sep 17 00:00:00 2001 From: =?UTF-8?q?=E7=BB=87=E4=B8=8D=E5=94=A7?= <168611353+XuezhiAsagiri@users.noreply.github.com> Date: Sat, 6 Sep 2025 10:54:47 +0800 Subject: [PATCH 06/10] Update risk.md MIME-Version: 1.0 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: 8bit 降QTc延长的风险移动到 用药风险中 Signed-off-by: 织不唧 <168611353+XuezhiAsagiri@users.noreply.github.com> --- content/zh-cn/docs/medicine/risk.md | 5 +++++ 1 file changed, 5 insertions(+) diff --git a/content/zh-cn/docs/medicine/risk.md b/content/zh-cn/docs/medicine/risk.md index c62d509f8e..f33442ff10 100644 --- a/content/zh-cn/docs/medicine/risk.md +++ b/content/zh-cn/docs/medicine/risk.md @@ -76,6 +76,8 @@ weight: 10 ## 抗雄激素制剂用药风险 +睾酮具有缩短 QT 间期（QTc）的作用[^35]，任何雄激素去除治疗（ADT），都可能会因睾酮下降/被阻断而出现 QTc 延长，而性腺功能不全者也观察到了 QTc 延长[^35][^36]。考虑到 GAHT 与 ADT 存在相当交集，在 GAHT 应关注 QTc 延长的情况，谨慎使用可能引起 QTc 延长的药物。 + ### 醋酸环丙孕酮 醋酸环丙孕酮（色谱龙）最常见的副作用有：**_阴道点状出血_、体重增加或减轻、抑郁、性欲降低、勃起功能障碍和精子产量减少（停药后可逆）**[^5] [^6] [^7]。\ @@ -167,6 +169,7 @@ weight: 10 - **雌二醇、人工孕激素和影响肝酶的药品：** 代谢可能受到 CYP3A4 抑制剂或诱导剂的影响[^2] [^6]。其中抑制剂使其代谢减慢；诱导剂使其代谢加快、疗效减弱。 - **螺内酯、人工孕激素和血浆蛋白：** 由于这两种抗雄制剂均与血浆白蛋白高度结合[^6] [^20] [^21]，不能排除其会跟其它强结合药物竞争白蛋白的可能。与此类药物并用时，二者的游离血药浓度均可能增加，导致其作用和副作用增强。可能需要降低其中一种强结合药物的剂量。这类药物包括抗抑郁药舍曲林[^27]。 - **雌二醇与血浆蛋白：** 生理水平下的雌二醇绝大部分与血浆蛋白结合，其中多数结合于白蛋白，少数结合于性激素结合球蛋白（SHBG）[^2] [^26]。虽然其会受到竞争白蛋白的其它药物影响，但由于雌二醇也会引起 SHBG 增加[^26]，故游离浓度变数可能较大。 +- **抗雄激素与可能引起 QT间期（QTc）延长的药品：** 与已知会延长 QT 间期或能诱导尖端扭转型室性心动过速的药物的合并用药进行仔细评价，如 IA 类（如奎尼丁、丙吡胺）或 III 类（如胺碘酮、索他洛尔、多非利特、伊布利特）抗心律失常药、美沙酮、莫西沙星、抗精神病药等[^10]。 - **共用 CYP3A4 代谢途径的药品：** 剂量较大时，相关副作用发生的风险可能增大[^7]。应以最低有效剂量服药。 - **酒精：** 已知酒精可降低醋酸环丙孕酮的效力[^5] [^6] [^7]。 @@ -227,3 +230,5 @@ Newsletter*, 2012, 22(4): 3-4. [^32]: Monroe S E, Levine L, Chang R J, et al. Prolactin-Secreting Pituitary Adenomas. V, Increased Gonadotroph Responsivity in Hyperprolactinemic Women with Pituitary Adenomas [J]. *The Journal of Clinical Endocrinology & Metabolism*, 1981, 52(6): 1171–1178. \[DOI: [10.1210/jcem-52-6-1171](https://doi.org/10.1210/jcem-52-6-1171)] [^33]: ANI Pharmaceuticals Inc. LITHOBID® U.S. Physicians Prescribing Information [EB/OL]. *Drugs@FDA*, 2022. [^34]: Taylor D M, Barnes T R E, Young A H. The Maudsley® Prescribing Guidelines in Psychiatry [M]. 14th ed. Hoboken, US: John Wiley & Sons, 2021: 851-855. +[^35]：Gheorghe G S, Hodorogea A S, Ciobanu A, et al. Androgen deprivation therapy, hypogonadism and cardiovascular toxicity in men with advanced prostate cancer[J]. Current Oncology, 2021, 28(5): 3331-3346. https://doi.org/10.3390/curroncol28050289 +[^36]：Gagliano-Jucá T, Travison T G, Kantoff P W, et al. Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer[J]. Journal of the Endocrine Society, 2018, 2(5): 485-496. https://doi.org/10.1210/js.2018-00039 From ebc857b5272865e3b8091586812fd157975709bf Mon Sep 17 00:00:00 2001 From: =?UTF-8?q?=E7=BB=87=E4=B8=8D=E5=94=A7?= <168611353+XuezhiAsagiri@users.noreply.github.com> Date: Sat, 6 Sep 2025 11:20:49 +0800 Subject: [PATCH 07/10] =?UTF-8?q?=E6=9B=B4=E6=96=B0=20risk.md?= MIME-Version: 1.0 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: 8bit --- content/zh-cn/docs/medicine/risk.md | 6 +++--- 1 file changed, 3 insertions(+), 3 deletions(-) diff --git a/content/zh-cn/docs/medicine/risk.md b/content/zh-cn/docs/medicine/risk.md index f33442ff10..bb192fecc6 100644 --- a/content/zh-cn/docs/medicine/risk.md +++ b/content/zh-cn/docs/medicine/risk.md @@ -76,7 +76,7 @@ weight: 10 ## 抗雄激素制剂用药风险 -睾酮具有缩短 QT 间期（QTc）的作用[^35]，任何雄激素去除治疗（ADT），都可能会因睾酮下降/被阻断而出现 QTc 延长，而性腺功能不全者也观察到了 QTc 延长[^35][^36]。考虑到 GAHT 与 ADT 存在相当交集，在 GAHT 应关注 QTc 延长的情况，谨慎使用可能引起 QTc 延长的药物。 +睾酮具有缩短 QT 间期（QTc）的作用[^35]，任何雄激素去除治疗（ADT），都可能会因睾酮下降/被阻断而出现 QTc 延长，而性腺功能不全者也观察到了 QTc 延长[^35] [^36]。考虑到 GAHT 与 ADT 存在相当交集，在 GAHT 应关注 QTc 延长的情况，谨慎使用可能引起 QTc 延长的药物。 ### 醋酸环丙孕酮 @@ -230,5 +230,5 @@ Newsletter*, 2012, 22(4): 3-4. [^32]: Monroe S E, Levine L, Chang R J, et al. Prolactin-Secreting Pituitary Adenomas. V, Increased Gonadotroph Responsivity in Hyperprolactinemic Women with Pituitary Adenomas [J]. *The Journal of Clinical Endocrinology & Metabolism*, 1981, 52(6): 1171–1178. \[DOI: [10.1210/jcem-52-6-1171](https://doi.org/10.1210/jcem-52-6-1171)] [^33]: ANI Pharmaceuticals Inc. LITHOBID® U.S. Physicians Prescribing Information [EB/OL]. *Drugs@FDA*, 2022. [^34]: Taylor D M, Barnes T R E, Young A H. The Maudsley® Prescribing Guidelines in Psychiatry [M]. 14th ed. Hoboken, US: John Wiley & Sons, 2021: 851-855. -[^35]：Gheorghe G S, Hodorogea A S, Ciobanu A, et al. Androgen deprivation therapy, hypogonadism and cardiovascular toxicity in men with advanced prostate cancer[J]. Current Oncology, 2021, 28(5): 3331-3346. https://doi.org/10.3390/curroncol28050289 -[^36]：Gagliano-Jucá T, Travison T G, Kantoff P W, et al. Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer[J]. Journal of the Endocrine Society, 2018, 2(5): 485-496. https://doi.org/10.1210/js.2018-00039 +[^35]：Gheorghe G S, Hodorogea A S, Ciobanu A, et al. Androgen deprivation therapy, hypogonadism and cardiovascular toxicity in men with advanced prostate cancer[J]. Current Oncology, 2021, 28(5): 3331-3346.https://doi.org/10.3390/curroncol28050289 +[^36]：Gagliano-Jucá T, Travison T G, Kantoff P W, et al. Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer[J]. Journal of the Endocrine Society,2018,2(5):485-496.https://doi.org/10.1210/js.2018-00039 From 13e71c30f027cbbaf96c6acba9a01d1786a19db6 Mon Sep 17 00:00:00 2001 From: =?UTF-8?q?=E7=BB=87=E4=B8=8D=E5=94=A7?= <168611353+XuezhiAsagiri@users.noreply.github.com> Date: Sat, 6 Sep 2025 11:33:20 +0800 Subject: [PATCH 08/10] Update risk.md MIME-Version: 1.0 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: 8bit Signed-off-by: 织不唧 <168611353+XuezhiAsagiri@users.noreply.github.com> --- content/zh-cn/docs/medicine/risk.md | 4 ++-- 1 file changed, 2 insertions(+), 2 deletions(-) diff --git a/content/zh-cn/docs/medicine/risk.md b/content/zh-cn/docs/medicine/risk.md index bb192fecc6..6ba15742ab 100644 --- a/content/zh-cn/docs/medicine/risk.md +++ b/content/zh-cn/docs/medicine/risk.md @@ -230,5 +230,5 @@ Newsletter*, 2012, 22(4): 3-4. [^32]: Monroe S E, Levine L, Chang R J, et al. Prolactin-Secreting Pituitary Adenomas. V, Increased Gonadotroph Responsivity in Hyperprolactinemic Women with Pituitary Adenomas [J]. *The Journal of Clinical Endocrinology & Metabolism*, 1981, 52(6): 1171–1178. \[DOI: [10.1210/jcem-52-6-1171](https://doi.org/10.1210/jcem-52-6-1171)] [^33]: ANI Pharmaceuticals Inc. LITHOBID® U.S. Physicians Prescribing Information [EB/OL]. *Drugs@FDA*, 2022. [^34]: Taylor D M, Barnes T R E, Young A H. The Maudsley® Prescribing Guidelines in Psychiatry [M]. 14th ed. Hoboken, US: John Wiley & Sons, 2021: 851-855. -[^35]：Gheorghe G S, Hodorogea A S, Ciobanu A, et al. Androgen deprivation therapy, hypogonadism and cardiovascular toxicity in men with advanced prostate cancer[J]. Current Oncology, 2021, 28(5): 3331-3346.https://doi.org/10.3390/curroncol28050289 -[^36]：Gagliano-Jucá T, Travison T G, Kantoff P W, et al. Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer[J]. Journal of the Endocrine Society,2018,2(5):485-496.https://doi.org/10.1210/js.2018-00039 +[^35]：Gheorghe G S, Hodorogea A S, Ciobanu A, et al. Androgen deprivation therapy, hypogonadism and cardiovascular toxicity in men with advanced prostate cancer[J]. Current Oncology, 2021, 28(5): 3331-3346. \[DOI: [10.3390/curroncol28050289](https://doi.org/10.3390/curroncol28050289)] +[^36]：Gagliano-Jucá T, Travison T G, Kantoff P W, et al. Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer[J]. Journal of the Endocrine Society,2018,2(5):485-496. \[DOI: [10.1210/js.2018-00039](https://doi.org/10.1210/js.2018-00039)］ From be47979fe8e1a741e59b7a8e190b9fbf6bb8fe69 Mon Sep 17 00:00:00 2001 From: =?UTF-8?q?=E7=BB=87=E4=B8=8D=E5=94=A7?= <168611353+XuezhiAsagiri@users.noreply.github.com> Date: Sat, 6 Sep 2025 11:51:43 +0800 Subject: [PATCH 09/10] Update risk.md MIME-Version: 1.0 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: 8bit Signed-off-by: 织不唧 <168611353+XuezhiAsagiri@users.noreply.github.com> --- content/zh-cn/docs/medicine/risk.md | 4 ++-- 1 file changed, 2 insertions(+), 2 deletions(-) diff --git a/content/zh-cn/docs/medicine/risk.md b/content/zh-cn/docs/medicine/risk.md index 6ba15742ab..329ab5b164 100644 --- a/content/zh-cn/docs/medicine/risk.md +++ b/content/zh-cn/docs/medicine/risk.md @@ -230,5 +230,5 @@ Newsletter*, 2012, 22(4): 3-4. [^32]: Monroe S E, Levine L, Chang R J, et al. Prolactin-Secreting Pituitary Adenomas. V, Increased Gonadotroph Responsivity in Hyperprolactinemic Women with Pituitary Adenomas [J]. *The Journal of Clinical Endocrinology & Metabolism*, 1981, 52(6): 1171–1178. \[DOI: [10.1210/jcem-52-6-1171](https://doi.org/10.1210/jcem-52-6-1171)] [^33]: ANI Pharmaceuticals Inc. LITHOBID® U.S. Physicians Prescribing Information [EB/OL]. *Drugs@FDA*, 2022. [^34]: Taylor D M, Barnes T R E, Young A H. The Maudsley® Prescribing Guidelines in Psychiatry [M]. 14th ed. Hoboken, US: John Wiley & Sons, 2021: 851-855. -[^35]：Gheorghe G S, Hodorogea A S, Ciobanu A, et al. Androgen deprivation therapy, hypogonadism and cardiovascular toxicity in men with advanced prostate cancer[J]. Current Oncology, 2021, 28(5): 3331-3346. \[DOI: [10.3390/curroncol28050289](https://doi.org/10.3390/curroncol28050289)] -[^36]：Gagliano-Jucá T, Travison T G, Kantoff P W, et al. Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer[J]. Journal of the Endocrine Society,2018,2(5):485-496. \[DOI: [10.1210/js.2018-00039](https://doi.org/10.1210/js.2018-00039)］ +[^35]: Gheorghe G S, Hodorogea A S, Ciobanu A, et al. Androgen deprivation therapy, hypogonadism and cardiovascular toxicity in men with advanced prostate cancer[J]. Current Oncology, 2021, 28(5): 3331-3346. \[DOI: [10.3390/curroncol28050289](https://doi.org/10.3390/curroncol28050289)] +[^36]: Gagliano-Jucá T, Travison T G, Kantoff P W, et al. Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer[J]. Journal of the Endocrine Society,2018,2(5):485-496. \[DOI: [10.1210/js.2018-00039](https://doi.org/10.1210/js.2018-00039)] From d148adf777fb0e1bbd910a4fc3f9eccf2213fe0c Mon Sep 17 00:00:00 2001 From: =?UTF-8?q?=E7=BB=87=E4=B8=8D=E5=94=A7?= <168611353+XuezhiAsagiri@users.noreply.github.com> Date: Sat, 6 Sep 2025 17:09:09 +0800 Subject: [PATCH 10/10] =?UTF-8?q?=E6=9B=B4=E6=96=B0=20risk.md?= MIME-Version: 1.0 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: 8bit --- content/zh-cn/docs/medicine/risk.md | 4 ++-- 1 file changed, 2 insertions(+), 2 deletions(-) diff --git a/content/zh-cn/docs/medicine/risk.md b/content/zh-cn/docs/medicine/risk.md index 329ab5b164..d168d92a60 100644 --- a/content/zh-cn/docs/medicine/risk.md +++ b/content/zh-cn/docs/medicine/risk.md @@ -229,6 +229,6 @@ Newsletter*, 2012, 22(4): 3-4. [^31]: Chung W G, Buhler D R. The Effect of Spironolactone Treatment on the Cytochrome P450-Mediated Metabolism of the Pyrrolizidine Alkaloid Senecionine by Hepatic Microsomes from Rats and Guinea Pigs [J]. *Toxicology and Applied Pharmacology*, 1994, 127(2): 314–319. \[DOI: [10.1006/taap.1994.1167](https://doi.org/10.1006/taap.1994.1167)] [^32]: Monroe S E, Levine L, Chang R J, et al. Prolactin-Secreting Pituitary Adenomas. V, Increased Gonadotroph Responsivity in Hyperprolactinemic Women with Pituitary Adenomas [J]. *The Journal of Clinical Endocrinology & Metabolism*, 1981, 52(6): 1171–1178. \[DOI: [10.1210/jcem-52-6-1171](https://doi.org/10.1210/jcem-52-6-1171)] [^33]: ANI Pharmaceuticals Inc. LITHOBID® U.S. Physicians Prescribing Information [EB/OL]. *Drugs@FDA*, 2022. -[^34]: Taylor D M, Barnes T R E, Young A H. The Maudsley® Prescribing Guidelines in Psychiatry [M]. 14th ed. Hoboken, US: John Wiley & Sons, 2021: 851-855. -[^35]: Gheorghe G S, Hodorogea A S, Ciobanu A, et al. Androgen deprivation therapy, hypogonadism and cardiovascular toxicity in men with advanced prostate cancer[J]. Current Oncology, 2021, 28(5): 3331-3346. \[DOI: [10.3390/curroncol28050289](https://doi.org/10.3390/curroncol28050289)] +[^34]: Taylor D M, Barnes T R E, Young A H. The Maudsley® Prescribing Guidelines in Psychiatry [M]. 14th ed. Hoboken, US: John Wiley & Sons, 2021: 851-855. +[^35]: Gheorghe G S, Hodorogea A S, Ciobanu A, et al. Androgen deprivation therapy, hypogonadism and cardiovascular toxicity in men with advanced prostate cancer[J]. Current Oncology, 2021, 28(5): 3331-3346. \[DOI: [10.3390/curroncol28050289](https://doi.org/10.3390/curroncol28050289)] [^36]: Gagliano-Jucá T, Travison T G, Kantoff P W, et al. Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer[J]. Journal of the Endocrine Society,2018,2(5):485-496. \[DOI: [10.1210/js.2018-00039](https://doi.org/10.1210/js.2018-00039)]